Tolerability of Ig20Gly During Onboarding in Patients With Primary Immunodeficiency Diseases

The subcutaneous immune globulin (SCIG) 20% product, Ig20Gly, was shown to be efficacious and well tolerated in two phase 2/3 North American and European studies at infusion volumes up to 60 mL/site and rates up to 60 mL/h/site in patients with primary immunodeficiency diseases.

Source: Annals of Allergy, Asthma and Immunology - June 18, 2019 Category: Allergy & Immunology Authors: Sudhir Gupta, Mark Stein, Iftikhar Hussain, Kenneth Paris, Werner Engl, Barbara McCoy, Christopher J. Rabbat, Leman Yel Source Type: research